Evidence map›Paper›PMID 24120954›Full record

ReviewAdvanced drug delivery reviews2013

Multidrug resistance: Physiological principles and nanomedical solutions.

Sijumon Kunjachan, Błażej Rychlik, Gert Storm, Fabian Kiessling, Twan Lammers

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 253 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Harnessing small extracellular vesicles for pro-oxidant delivery: novel approach for drug-sensitive and resistant cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Antimicrobial-ResistantFoods (Basel, Switzerland) · 2023
    Article
  14. Review
  15. Stimuli-Responsive Boron-Based Materials in Drug Delivery.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Sijumon Kunjachan *Department of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
Błażej Rychlik *Cytometry Lab, Department of Molecular Biophysics, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
Gert StormDepartment of Controlled Drug Delivery, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands.
Fabian KiesslingDepartment of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
Twan LammersDepartment of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.
RWTH Aachen University · DEUniversity of Łódź · PLUniversity of Twente · NLUtrecht University · NL

Funding

European Research Council 309495
6 · The paper itself

Abstract

Multidrug resistance (MDR) is a pathophysiological phenomenon employed by cancer cells which limits the prolonged and effective use of chemotherapeutic agents. MDR is primarily based on the over-expression of drug efflux pumps in the cellular membrane. Prominent examples of such efflux pumps, which belong to the ATP-binding cassette (ABC) superfamily of proteins, are Pgp (P-glycoprotein) and MRP (multidrug resistance-associated protein), nowadays officially known as ABCB1 and ABCC1. Over the years, several strategies have been evaluated to overcome MDR, based not only on the use of low-molecular-weight MDR modulators, but also on the implementation of 1-100(0) nm-sized drug delivery systems. In the present manuscript, after introducing the most important physiological principles of MDR, we summarize prototypic nanomedical strategies to overcome multidrug resistance, including the use of carrier materials with intrinsic anti-MDR properties, the use of nanomedicines to modify the mode of cellular uptake, and the co-formulation of chemotherapeutic drugs together with low- and high-molecular-weight MDR inhibitors within a single drug delivery system. While certain challenges still need to be overcome before such constructs and concepts can be widely applied in the clinic, the insights obtained and the progress made strongly suggest that nanomedicine formulations hold significant potential for improving the treatment of multidrug-resistant malignancies.

Indexed as

ATP-Binding Cassette TransportersDrug Resistance, MultipleAnimalsCell Line, TumorCell SurvivalDrug CarriersHumansMolecular Targeted TherapyNanomedicineNanostructuresOrgan SpecificityPharmaceutical PreparationsProtein TransportSubstrate SpecificityATP-Binding Cassette TransportersDrug CarriersPharmaceutical PreparationsABC transportersDrug efflux pumpsDrug targetingMDRMRPMultidrug resistanceNanomedicinePgpPluronicssiRNA

Identifiers

PMID24120954
PMCPMC3939439
OpenAlexW1985498995

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.